Cue Biopharma Lines Up $50M Private Placement Led by Cormorant

Balance-sheet strength separates the clinical-stage biotechs that reach their catalysts from those that stall, and Cue Biopharma just added a cushion. The company announced a $50.0 million private placement led by Cormorant Asset Management, with participation from Columbia Threadneedle Investments.

Cue Biopharma is a clinical-stage company designing biologics intended to selectively engage the immune system toward functional cures for immunological disorders.

The upside case is straightforward runway. Under the securities purchase agreement, Cue is selling 1,418,071 shares at $33.21 apiece, along with pre-funded warrants for up to 87,500 shares, for roughly $50.0 million in gross proceeds. The transaction is expected to close on or about July 13, 2026, with net proceeds earmarked to fund clinical development and general corporate purposes. Backing from a specialist healthcare investor like Cormorant is often read as a vote of confidence in the underlying pipeline.

A private placement dilutes existing holders and provides cash without de-risking the science, which must still deliver in the clinic. This is market commentary, not investment advice — small-cap biotech stocks are highly speculative and you can lose your entire investment.